COL3A1 has been shown to be associated with poor prognosis and drug resistance in GBM patients (Gao et al., 2016), so we mainly focused on whether MFAP4 plays an important role in the development of gliomas. This evidence concerns the gene MFAP4 and central nervous system cancer.